Genelux Corporation (GNLX) Stock

Genelux Corporation (GNLX) is a Healthcare stock trading at $2.96 (as of 2026-06-18), with a market capitalization of $136.76M and a trailing P/E of -3.5. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary, modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small-cell lung cancer. The company is also developing V2ACT Immunotherapy for the treatment of pancreatic cancer; and V-VET1 to treat hematologic and solid cancer. The company was incorporated in 2001 and is headquartered in Westlake Village, California.

Valuation — source: SEC EDGAR (first-party)
Price$2.96
Market Cap$136.76M
P/E Ratio-3.5
EV / EBITDA-3.6
Price / Book5.80
Price / Sales-44317.28
DCF Value (model)$-9.90
DCF Upside vs Price-433.9%
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$8000.00
Net Margin-401812.5%
Return on Equity-146.5%
Debt / Equity0.04
Current Ratio3.68
Revenue Growth (YoY)0.0%
EPS Growth (YoY)-9.5%
FCF Growth (YoY)22.0%
Financial Health — source: SEC EDGAR
Altman Z-Score-15.41 (distress)
Valuation vs Sector & Industry
Stock P/E-3.5
Sector P/E (Healthcare)20.9
Industry P/E (Pharmaceutical Products)17.0
vs Sector-116.7%
vs Industry-120.5%
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderVANGUARD GROUP INC ($6.76M)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryPharmaceutical Products
CEOThomas D. Zindrick
Employees24
CountryUS
IPO Date2023-01-26

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

  • Neonc Technologies Holdings, Inc. (NTHI)
  • SAB Biotherapeutics, Inc. (SABS)
  • Arcturus Therapeutics Holdings Inc. (ARCT)
  • Minerva Neurosciences, Inc. (NERV)
  • Alector, Inc. (ALEC)
  • Coherus Oncology, Inc. (CHRS)
  • LifeVantage Corporation (LFVN)
  • Caribou Biosciences, Inc. (CRBU)
GNLX earnings history · GNLX institutional & insider holders · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.